WallStSmart
BTAI

BioXcel Therapeutics Inc

NASDAQ: BTAI · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.04
-1.89% today

Updated 2026-04-29

Market cap
$28.70M
P/E ratio
P/S ratio
44.70x
EPS (TTM)
$-5.73
Dividend yield
52W range
$1 – $8
Volume
1.8M

BioXcel Therapeutics Inc (BTAI) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$24.00$0.00$375000.00$1.38M$2.27M$642000.00
Revenue growth (YoY)-100.0%+268.0%+64.2%-71.7%
Cost of revenue$0.00$1000.00$17000.00$156000.00$188000.00$297000.00$20000.00$1.26M$2.14M$464000.00
Gross profit$0.00$-1000.00$-17000.00$-156000.00$24.00$-297000.00$355000.00$120000.00$123000.00$178000.00
Gross margin100.0%94.7%8.7%5.4%27.7%
R&D$233000.00$1.40M$2.69M$14.56M$25.80M$57.99M$52.71M$91.24M$84.33M$30.43M$30.25M
SG&A$403000.00$721000.00$1.85M$5.40M$7.80M$24.30M$54.23M$55.76M$63.51M$33.10M$20.49M
Operating income$-636000.00$-2.12M$-4.54M$-19.96M$-33.60M$-82.30M$-106.94M$-159.65M$-171.78M$-67.25M$-49.70M
Operating margin-342904166.7%-42572.0%-12448.0%-2967.6%-7742.2%
EBITDA$-636000.00$-2.12M$-4.54M$-19.25M$-32.81M$-82.11M$-106.64M$-157.22M$-165.42M$-44.16M$-49.41M
EBITDA margin-342120833.3%-41924.5%-11987.0%-1948.9%-7695.5%
EBIT$-2.12M$-4.54M$-19.27M$-32.97M$-82.30M$-106.94M$-157.54M$-165.74M$-44.47M$-49.70M
Interest expense$0.00$0.00$2000.00$0.00$0.00$27000.00$40000.00$8.21M$13.31M$15.13M$16.98M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-636000.00$-2.12M$-4.54M$-19.27M$-32.34M$-82.01M$-106.63M$-165.76M$-179.05M$-59.60M$-69.90M
Net income growth (YoY)-233.3%-114.1%-324.5%-67.8%-153.6%-30.0%-55.5%-8.0%+66.7%-17.3%
Profit margin-341700000.0%-44201.9%-12974.9%-2630.1%-10887.4%